Horizon Drops as Investors Doubt Company’s Marketing

Horizon Pharma Inc., a maker of pain therapies, fell the most ever in New York trading as investors doubted the company’s ability to market its newly approved Rayos rheumatoid arthritis treatment.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.